PTC Therapeutics, Inc. Capital Expenditures Incurred but Not yet Paid
PTC Therapeutics, Inc. (PTCT) reported Capital Expenditures Incurred but Not yet Paid of $593.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2026-07-30
- PTC Therapeutics, Inc. capital expenditures incurred but not yet paid for the quarter ending 2023-06-30 was $8.00K.
- PTC Therapeutics, Inc. capital expenditures incurred but not yet paid for the quarter ending 2023-03-31 was $28.00K.
- PTC Therapeutics, Inc. capital expenditures incurred but not yet paid for fiscal 2025 was $126.00K, a 80.00% increase from fiscal 2024.
- PTC Therapeutics, Inc. capital expenditures incurred but not yet paid for fiscal 2024 was $70.00K.
- PTC Therapeutics, Inc. capital expenditures incurred but not yet paid for fiscal 2022 was $308.00K.
- PTC Therapeutics, Inc. capital expenditures incurred but not yet paid for fiscal 2020 was $1.06M.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|
| 2026-06-30 | $593.00K 10-Q · filed 2026-07-30 | ||
| 2025-12-31 | $126.00K 10-K · filed 2026-02-19 | ||
| 2024-12-31 | $70.00K 10-K · filed 2026-02-19 | ||
| 2023-06-30 | $8.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $36.00K 10-Q · filed 2024-08-08 | |
| 2023-03-31 | $28.00K 10-Q · filed 2024-04-25 | ||
| 2022-12-31 | $308.00K 10-K · filed 2025-02-27 | ||
| 2020-12-31 | $1.06M 10-K · filed 2023-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |